Europe Anti-snoring Device Market - Consumer Trends & Forecast 2026-2034

Europe Anti-snoring Device Market Size and Forecast 2026-2034

Europe Anti-snoring Device Market is expected to reach US$ 987.03 Million by 2034 from US$ 520.89 Million in 2025, with a CAGR of 7.36% from 2026 to 2034. The Europe anti-snoring device market is growing due to rising awareness of sleep disorders, increasing prevalence of obstructive sleep apnea, growing adoption of non-invasive treatment options, technological advancements in oral appliances and wearables, and expanding access to sleep healthcare services.

Europe Anti-snoring Device Industry Overview

Anti-snoring devices are products designed to reduce or eliminate snoring by improving airflow through the upper airway during sleep. These devices include mandibular advancement devices (MADs), tongue-stabilizing devices, nasal dilators, chin straps, positional therapy devices, and smart wearable solutions. They are commonly used by individuals suffering from primary snoring and mild-to-moderate obstructive sleep apnea (OSA). Anti-snoring devices offer a non-invasive alternative to surgical procedures and continuous positive airway pressure (CPAP) therapy. Increasing awareness regarding the health risks associated with untreated snoring, coupled with technological advancements and growing demand for home-based sleep solutions, is driving market adoption across Europe.

The Europe anti-snoring device market is experiencing steady growth due to the increasing prevalence of sleep-disordered breathing conditions and rising awareness regarding sleep health. A growing elderly population, increasing obesity rates, and higher diagnosis rates of obstructive sleep apnea are expanding the target patient population. Consumers are increasingly seeking comfortable, non-invasive alternatives to CPAP therapy, driving demand for oral appliances, positional therapy devices, and smart sleep technologies. Additionally, advancements in digital dentistry, 3D printing, wearable sensors, and customized oral devices are enhancing treatment effectiveness and patient compliance. Expanding telehealth services and improved access to sleep disorder management are further supporting market growth across Europe.

Recent Developments in Europe Anti-snoring Device Market

• Following FDA 510(k) clearance, SnoreLessNow introduced the Anti Snore Mouth Guard+, marketed in Europe as SomnoFit-S(R). The mandibular advancement device is designed to gently reposition the lower jaw forward during sleep, helping to maintain an open airway and reduce snoring. The product provides a comfortable, non-invasive alternative to CPAP therapy for individuals seeking effective snoring management without the use of masks or powered equipment.

Growth Drivers for the Europe Anti-snoring Device Market

Increasing Demand for Comfortable and Customizable Oral Appliances

The growing preference for comfortable and personalized anti-snoring solutions is a major driver of the European market. Traditional snoring treatments often suffer from low patient compliance due to discomfort and inconvenience. As a result, manufacturers are increasingly focusing on customized oral appliances that provide improved fit, comfort, and effectiveness. Digital dentistry and advanced manufacturing technologies are enabling the production of highly individualized devices that can be tailored to patient-specific anatomical requirements. These innovations improve treatment adherence and clinical outcomes while supporting broader adoption among individuals seeking non-invasive snoring management options. Growing consumer awareness of sleep quality and the availability of direct-to-consumer solutions are also contributing to increased demand across Europe.

In December 2024, ZQuiet introduced the ZQuiet Advance Anti-Snoring Mouthpiece, featuring an adjustable custom-fit design and enhanced comfort-focused engineering to improve snoring relief and user compliance.

Advancements in Digital and 3D-Printed Sleep Therapy Devices

Technological innovation is transforming the anti-snoring device market through the introduction of digitally designed and 3D-printed treatment solutions. Advanced manufacturing techniques improve precision, customization, and patient comfort while reducing production time. These innovations enable healthcare providers to deliver more effective oral appliances with enhanced durability and fit. The adoption of digital workflows in dentistry and sleep medicine is also supporting wider use of customized snoring management devices. As patients increasingly seek discreet and convenient treatment options, manufacturers are investing in next-generation products that combine advanced materials with digital design capabilities. This trend is expected to accelerate market growth throughout Europe.

In May 2024, Glidewell launched the Digital Silent Nite(R) 3D Sleep Appliance, a fully digital, 3D-printed mandibular advancement device developed to alleviate snoring and mild-to-moderate obstructive sleep apnea.

Growing Adoption of Innovative Sleep Apnea and Snoring Therapies

The increasing need for alternatives to CPAP therapy is driving demand for innovative anti-snoring and sleep apnea treatments. Patients are seeking solutions that offer greater comfort, mobility, and long-term adherence. Manufacturers are responding by introducing advanced oral appliances, neuromodulation systems, and integrated sleep technologies that address both snoring and obstructive sleep apnea. Rising diagnosis rates and growing investments in sleep medicine are supporting the adoption of these solutions across Europe. As healthcare providers focus on improving patient outcomes through personalized therapies, the market is witnessing increased demand for innovative treatment options.

In December 2024, Nyxoah announced the commercial launch of its Genio(R) therapy in England, providing patients with an innovative neurostimulation-based treatment option for obstructive sleep apnea and related snoring conditions.

Challenges in the Europe Anti-snoring Device Market

Limited Consumer Awareness and Underdiagnosis

A major challenge facing the European anti-snoring device market is the underdiagnosis of sleep-related breathing disorders. Many individuals consider snoring a lifestyle issue rather than a medical condition, delaying diagnosis and treatment. Consequently, a significant proportion of potential users remain unaware of available treatment options. Additionally, access to sleep studies and specialist consultations varies across European countries, leading to differences in diagnosis rates. Limited public understanding of the relationship between chronic snoring and obstructive sleep apnea further restricts market penetration. Improving education regarding sleep health and expanding screening initiatives will be important for increasing adoption of anti-snoring devices across the region.

Product Compliance and Comfort Concerns

Although anti-snoring devices offer non-invasive treatment options, maintaining long-term patient compliance remains challenging. Some users experience discomfort, jaw soreness, nasal irritation, or difficulty adapting to oral appliances and positional therapy devices. These issues may reduce treatment adherence and lead patients to discontinue use. Individual anatomical differences can also influence device effectiveness, creating variability in treatment outcomes. Furthermore, consumers may be hesitant to invest in premium products without clear evidence of long-term benefits. Manufacturers must continue improving device design, customization, and comfort while providing clinical evidence supporting effectiveness to encourage sustained usage and strengthen market acceptance.

France Anti-snoring Device Market

France is a significant market for anti-snoring devices due to growing awareness of sleep apnea, rising obesity rates, and increasing utilization of sleep diagnostic services. Demand is particularly strong for oral appliances and neurostimulation therapies that offer alternatives to CPAP treatment. The country's well-established healthcare system and growing focus on sleep health are supporting adoption of innovative snoring management solutions.

In July 2024, Inspire Medical Systems announced the nationwide reimbursement and commercialization expansion of Inspire(R) Therapy in France. The implantable hypoglossal nerve stimulation device is designed for patients with moderate-to-severe obstructive sleep apnea who are unable to tolerate CPAP therapy. The reimbursement approval significantly expanded patient access to the therapy across France.

Germany Anti-snoring Device Market

Germany remains the largest anti-snoring device market in Europe, supported by a strong sleep medicine infrastructure, widespread diagnosis of sleep disorders, and high adoption of advanced treatment technologies. The country has numerous accredited sleep laboratories and specialized clinics that facilitate the use of oral appliances and innovative sleep therapies. Growing awareness of the health risks associated with untreated snoring continues to drive demand.

In October 2025, Smartee launched the Smartee Sleep Aligner, the world's first clear aligner designed to address primary snoring and obstructive sleep apnea while simultaneously providing orthodontic correction. The product offers a discreet and patient-friendly treatment option that aligns with Germany's growing demand for innovative oral sleep therapies.

Italy Anti-snoring Device Market

Italy's anti-snoring device market is expanding due to increasing awareness of sleep health, rising prevalence of obesity-related sleep disorders, and growing acceptance of non-invasive treatment options. Oral appliance therapy is gaining traction among patients seeking alternatives to CPAP treatment. Technological advancements in customized dental sleep devices are also supporting market development.

In July 2025, Vivos Therapeutics received expanded commercialization support for its VidaSleep(TM) Oral Appliance, a patented device developed for the treatment of snoring and mild-to-moderate obstructive sleep apnea. The appliance utilizes the company's proprietary technology to improve airway function and supports the growing adoption of oral appliance therapy across European markets, including Italy.

Spain Anti-snoring Device Market

Spain is experiencing increasing demand for anti-snoring devices due to rising awareness of sleep-disordered breathing, growing healthcare expenditure, and increasing adoption of home-based sleep solutions. Consumers are showing greater interest in convenient and non-invasive technologies that improve sleep quality and reduce snoring. Expanding sleep clinic networks are also supporting market growth.

In November 2025, Quiet Lab announced the launch of the Quiet Lab Mouthpiece, a scientifically engineered anti-snoring oral device developed to improve nighttime airflow and reduce snoring. The product incorporates advanced dental biomechanics and respiratory science principles to provide a comfortable, non-powered solution for snoring management. The launch strengthens the availability of innovative oral anti-snoring devices in European markets, including Spain.

Europe Oral Anti-Snoring Appliances Market

The Europe Oral Anti-Snoring Appliances market is experiencing steady growth due to increasing awareness of sleep-disordered breathing and the rising preference for non-invasive treatment options. Oral appliances, particularly mandibular advancement devices (MADs) and tongue-retaining devices, are widely used to reduce snoring by maintaining an open airway during sleep. These devices are gaining popularity among patients with primary snoring and mild-to-moderate obstructive sleep apnea who seek alternatives to continuous positive airway pressure (CPAP) therapy. Advances in digital dentistry, 3D scanning, and customized appliance manufacturing have improved comfort, fit, and treatment effectiveness. Additionally, increasing involvement of dentists in sleep medicine and growing acceptance of oral appliance therapy are supporting market expansion across Europe throughout the forecast period.

Europe Anti-Snoring Devices Retail Pharmacies Market

The Europe Anti-Snoring Devices Retail Pharmacies market represents an important distribution channel, driven by the accessibility and convenience offered by retail pharmacy networks. Consumers frequently purchase over-the-counter anti-snoring products such as nasal dilators, nasal strips, chin straps, and entry-level oral appliances through pharmacy outlets. Retail pharmacies provide consumers with easy access to snoring management solutions without requiring specialist consultations, making them a preferred purchasing channel for mild snoring cases. Growing consumer awareness of sleep health and increasing demand for self-care products are supporting sales through pharmacy chains across Europe. Furthermore, pharmacists play a valuable role in educating consumers about available treatment options and guiding product selection, contributing to the continued growth of this market segment.

Europe Homecare Anti-Snoring Devices Market

The Europe Homecare Anti-Snoring Devices market is growing rapidly as consumers increasingly seek convenient and cost-effective solutions for managing snoring and mild sleep-disordered breathing conditions at home. Homecare devices include oral appliances, nasal dilators, positional therapy products, chin straps, wearable sleep monitors, and other non-invasive solutions designed for independent use. Rising awareness regarding the impact of poor sleep quality on overall health is encouraging consumers to adopt home-based treatment options. The expansion of e-commerce platforms and direct-to-consumer sales channels has further improved product accessibility across Europe. In addition, technological advancements in smart sleep devices and connected monitoring systems are enhancing user experience and treatment effectiveness. These factors continue to support strong growth within the European homecare anti-snoring devices market.

Research Methodology of the Europe Anti-snoring Device Market

Step 1: Market Definition and Scope

The Europe Anti-Snoring Device Market was first defined according to devices specifically designed to reduce or manage snoring.

The scope included:

• Mandibular advancement devices (MADs)
• Nasal dilators
• Nasal strips
• Nasal clips
• Tongue-retaining devices
• Chin straps
• Positional therapy devices
• Anti-snoring pillows and specialized positioning products
• Wearable anti-snoring devices
• Electronic anti-snoring devices
• Other anti-snoring devices and accessories

The study clearly distinguished anti-snoring devices from continuous positive airway pressure (CPAP) systems, since CPAP was primarily a treatment for obstructive sleep apnea rather than a conventional anti-snoring product.

Similarly, general sleep products such as ordinary pillows, mattresses, and unrelated sleep-tracking devices were excluded unless they had a specific anti-snoring function.

Where a product was marketed for both snoring and obstructive sleep apnea, only the portion attributable to anti-snoring applications was included.

Step 2: Estimate the Potential Snoring Population

The estimation was initiated by determining the population experiencing habitual or clinically relevant snoring across European countries.

The model considered:

• Adult population
• Male and female population
• Age distribution
• Overweight and obesity prevalence
• Sleep-disordered breathing
• Obstructive sleep apnea prevalence
• Household awareness of snoring
• Diagnosis and treatment rates, etc.

Country-level estimates were developed for major markets such as Germany, France, United Kingdom, Italy, Spain, Netherlands, Switzerland, Belgium, Sweden, Denmark, Norway, Austria, and other European countries.

The potential user population was then narrowed to individuals who represented a realistic addressable market for anti-snoring devices.

Step 3: Determine the Addressable Device Population

Not every person who snored was assumed to purchase an anti-snoring device.

Therefore, the model applied successive filters:

Total Adult Population

↓

Estimated Snoring Population

↓

Habitual/Problem Snoring Population

↓

Awareness of Snoring

↓

Treatment-Seeking Population

↓

Device-Eligible Population

↓

Anti-Snoring Device Users

This approach prevented the market from being overstated by multiplying the entire snoring population by an assumed device price.

Step 4: Estimate Device Adoption

The number of actual device users was calculated by applying an adoption rate to the addressable population.

The formula was:

Anti-Snoring Device Users = Addressable Snoring Population X Device Adoption Rate

Adoption rates were estimated separately by country and device category.

The assumptions considered:

• Consumer awareness
• Physician recommendation
• Dental consultation
• Sleep-clinic referrals
• Online availability
• Pharmacy distribution
• Insurance/reimbursement
• Disposable versus reusable products
• Consumer willingness to purchase
• Product effectiveness
• Price, etc.

Step 5: Apply Device Utilization and Replacement Frequency

After determining the number of users, annual device requirements were estimated.

For reusable products:

Annual Units = Active Users X Replacement Frequency

For disposable or frequently replaced products:

Annual Units = Active Users X Annual Consumption per User

Different replacement cycles were applied to mandibular advancement devices, nasal strips, nasal dilators, electronic devices, and other product categories.

Step 6: Establish Average Selling Price

An average selling price was then determined for each anti-snoring device category.

Pricing was differentiated according to:

• Device type
• Brand
• Product quality
• Prescription versus OTC
• Custom versus ready-made device
• Country
• Online versus offline channel
• Dental-clinic versus retail sales
• Disposable versus reusable products, etc.

A weighted ASP was calculated as:

Weighted ASP = Σ (Product Units X Product ASP) ÷ Total Product Units

Manufacturer/distributor prices were used where possible for market-value calculations, while retail prices were used as a supporting reference.

Step 7: Build the Bottom-Up Market Estimate

The bottom-up approach was used as the primary market-estimation method.

The core calculation was:

Europe Anti-snoring Device Market = Σ (Users X Annual Device Requirement per User X ASP)

The calculation was performed separately for:

• Mandibular advancement devices
• Nasal devices
• Tongue-retaining devices
• Positional devices
• Electronic/wearable devices
• Other anti-snoring devices

The country-level results were then aggregated to determine the European market.

Step 8: Estimate Mandibular Advancement Device Market Separately

Mandibular advancement devices were modelled separately because their purchasing pathway and ASP differed substantially from inexpensive nasal strips and other OTC products.

The calculation considered:

Eligible Snoring/OSA Population X MAD Adoption Rate X Annual Replacement Requirement X Average MAD Price

The analysis differentiated between:

• Custom-made MADs
• Thermoplastic/boil-and-bite devices
• Dentist-fitted devices
• Over-the-counter MADs

Dental-clinic distribution and physician/sleep-specialist recommendations were incorporated into the model.

Step 9: Estimate Nasal Anti-Snoring Devices

Nasal products were estimated using a consumption-based approach.

The calculation considered:

Number of Users X Average Products Used per Year X Average Selling Price

For reusable nasal dilators, replacement frequency was applied.

For disposable nasal strips, annual consumption was estimated based on the average number of strips used per week or month.

This category was modelled separately because its unit price was substantially lower but purchase frequency could be significantly higher than that of reusable anti-snoring devices.

Step 10: Estimate Positional and Electronic Devices

Positional therapy and electronic anti-snoring devices were estimated based on the number of users adopting technology-based approaches.

The model incorporated:

• Device installations
• Wearable adoption
• Replacement cycles
• Technology upgrades
• Average selling price
• Smartphone connectivity
• Sleep-monitoring functionality

Devices marketed for both snoring reduction and sleep monitoring were included only to the extent that their value could reasonably be attributed to the anti-snoring application.

Step 11: Retail and Distribution Channel Validation

The bottom-up estimate was validated through channel-level sales.

The analysis considered:

• Pharmacies
• Hospitals
• Dental clinics
• Sleep clinics
• Specialty medical-device stores
• Supermarkets
• E-commerce
• Manufacturer websites
• Other retail channels

For each channel, the number of products sold, average price, distribution margins, and product mix were assessed.

E-commerce was treated separately because anti-snoring products such as nasal strips and OTC mandibular advancement devices could be purchased directly by consumers.

Step 12: Company-Level Validation

The market estimate was then cross-checked against revenues and unit sales of manufacturers and brands operating in the European anti-snoring and oral-appliance market.

The analysis considered:

• Anti-snoring device revenue
• Product sales volume
• European revenue
• Number of distributors
• Dental-clinic partnerships
• Product launches
• E-commerce sales
• Geographic presence
• Manufacturing capacity

Where companies reported broader sleep-care or oral-health revenues, the anti-snoring component was estimated using product portfolios and geographic exposure.

Step 13: Sleep-Clinic and Dental-Channel Validation

The number of sleep clinics, dental practices, sleep specialists, and relevant healthcare professionals was used to validate the addressable market for clinically oriented devices.

This was particularly important for custom mandibular advancement devices, because their sales could involve dental assessment, fitting, follow-up, and replacement rather than simple retail purchase.

The analysis therefore distinguished between:

Consumer-led purchase

and

Clinician-recommended or clinician-fitted purchase

to avoid applying a single adoption rate across all products.

Step 14: Top-Down Validation

A top-down approach was then applied as an independent validation.

The calculation was structured as:

European Sleep-Disorder/Anti-Snoring Product Market X Anti-Snoring Device Share = Europe Anti-Snoring Device Market

A second validation could have been based on:

Estimated Snoring Population X Device Penetration X Average Annual Device Spending

The penetration and spending assumptions were derived from consumer surveys, clinical literature, company information, retail prices, healthcare statistics, and primary research rather than arbitrary assumptions.

Step 15: Regulatory Validation

The regulatory status of products was reviewed because anti-snoring devices could fall under different regulatory categories depending on their intended purpose and claims.

Products classified as medical devices were assessed against the European Union's Medical Device Regulation (EU) 2017/745 (MDR).

The European Commission's medical-device framework had strengthened requirements concerning device safety, clinical evidence, conformity assessment, and post-market surveillance.

The European Commission's EUDAMED system had also become more relevant for market validation, with the actor-registration, UDI/device-registration, notified-bodies/certificates, and market-surveillance modules becoming mandatory from 28 May 2026.

EUDAMED device-registration information could therefore be used as a supporting source when identifying manufacturers and medical devices placed on the EU market.

Step 16: Import-Export Validation

Trade statistics were used as an additional supply-side cross-check.

The apparent domestic supply was calculated as:

Domestic Production + Imports - Exports = Apparent Domestic Supply

Relevant customs classifications were reviewed for:

• Oral appliances
• Nasal devices
• Medical breathing devices
• Sleep-related devices
• Plastic/medical appliances
• Electronic anti-snoring devices

Because customs codes could include products outside the anti-snoring category, trade statistics were treated as a supporting validation source rather than the primary market estimate.

Step 17: Third Validation and Market Triangulation

The final market estimate was triangulated using three independent approaches:

A. Bottom-Up Consumer Approach

Snoring population X addressable population X adoption rate X device requirement X ASP.

B. Top-Down Market Approach

Sleep-related/medical-device market X anti-snoring device share.

C. Supply-Side Approach

Manufacturer revenues + distributor sales + retail/e-commerce sales + import/export data.

The three estimates were compared and discrepancies were investigated based on:

• Medical versus consumer products
• Prescription versus OTC devices
• Custom versus ready-made products
• Retail versus manufacturer pricing
• Reusable versus disposable devices
• Cross-border purchases
• E-commerce sales
• Products marketed for both snoring and sleep apnea
• Distributor margins
• Replacement cycles

The final market value was established after reconciling these differences rather than simply averaging the three estimates.

Step 18: Country-Level Market Estimation

The European market was estimated separately for individual countries before being aggregated.

The country-level model considered:

• Adult population
• Snoring prevalence
• Obesity prevalence
• Sleep-disorder awareness
• Treatment-seeking behaviour
• Device penetration
• Healthcare infrastructure
• Dental-clinic availability
• Sleep-clinic infrastructure
• E-commerce penetration
• Product prices
• Reimbursement environment

The calculation was structured as:

Germany + France + United Kingdom + Italy + Spain + Netherlands + Switzerland + Belgium + Nordics + Austria + Poland + Rest of Europe = Europe Anti-snoring Device Market

This country-level approach was used because consumer awareness, healthcare access, dental treatment pathways, and product prices differed across European markets.

Step 19: Historical Market Estimation

Historical market values were estimated using historical snoring populations, device penetration, unit sales, ASPs, replacement rates, company revenues, retail prices, and distribution information.

Historical ASPs were applied to the corresponding years rather than using current prices retrospectively.

Changes in consumer awareness, online purchasing, product availability, clinical adoption of oral appliances, and sleep-health awareness were also incorporated.

Step 20: Market Forecasting

The future Europe Anti-snoring Device Market was forecast based on expected changes in the addressable snoring population, device adoption, replacement frequency, product innovation, and average selling prices.

The basic forecasting formula was:

Future Market = Future Active Device Users X Annual Device Requirement per User X Future ASP

The forecast incorporated:

• Aging population
• Increasing awareness of sleep-related disorders
• Rising obesity prevalence
• Greater awareness of snoring and sleep apnea
• Increasing consumer interest in non-invasive solutions
• Growth of oral appliance therapy
• Expansion of dental sleep medicine
• E-commerce penetration
• Product innovation
• Wearable technology
• Smartphone-connected sleep devices
• Improved clinical recognition of sleep-disordered breathing

Growth assumptions were applied separately by country and product category rather than using a uniform European growth rate.

Core Market Formula

Europe Anti-snoring Device Market = Σ [Active Device Users X Annual Device Requirement per User X Average Selling Price]

The bottom-up user-based approach was used as the foundation, while company revenues, retail and e-commerce sales, dental and sleep-clinic activity, regulatory information, healthcare statistics, and import/export data were used as independent validation layers. The methodology also separated clinically oriented devices from consumer products, which was particularly important for accurately estimating the European anti-snoring device market.

Market Segmentations

Product

• Oral Appliances
• Nasal Devices
• Tongue-Stabilizing Devices
• Chin Straps
• Position Control Devices
• Expiratory Positive Airway Pressure (EPAP) Therapy Devices

Distribution Channel

• Retail Pharmacies
• Online Stores

End User

• Homecare
• Others

Countries

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Russia
• Poland
• Greece
• Norway
• Romania
• Portugal
• Rest of Europe

All the Key players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Koninklijke Philips N.V.
• ResMed, Inc.
• SomnoMed Limited
• GSK Plc.
• Apnea Sciences Corporation
• ZQuiet (Sleeping Well, LLC)
• Airway Management, Inc.
• Fisher & Paykel Healthcare Limited.
• Tomed GmbH